Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Medicinas Complementares
Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Life Sci ; 55(7): 479-83, 1994.
Artigo em Inglês | MEDLINE | ID: mdl-8041227

RESUMO

Nefazodone (2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl- 2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one) has been reported to be effective in the treatment of depression. Antagonism of serotonin type 2A (5HT2A) receptors, as well as inhibition of the serotonin (5HT) uptake carrier, has been suggested to contribute to the antidepressant action of nefazodone in vivo (Eison et al., 1990). Nefazodone weakly antagonized the quipazine-induced rise in rat serum corticosterone levels and the quipazine-induced increase in rat hypothalamic 3-methoxy-4-hydroxy-phenylglycol sulfate, suggesting blockade of 5HT2A receptors in vivo. Nefazodone, however, failed to antagonize the p-chloroamphetamine-induced depletion of mouse or rat brain 5HT, displaying a lack of effect on the 5HT uptake carrier. These data extend previous in vitro and in vivo data (Eison, et al. 1990) reporting nefazodone to be an antagonist at 5HT2A receptors, but fail to show inhibition of the 5HT uptake carrier in the same dose range.


Assuntos
Inibidores Seletivos de Recaptação de Serotonina/farmacologia , Antagonistas da Serotonina/farmacologia , Triazóis/farmacologia , Animais , Hipotálamo/efeitos dos fármacos , Hipotálamo/metabolismo , Masculino , Metoxi-Hidroxifenilglicol/farmacologia , Camundongos , Camundongos Endogâmicos ICR , Piperazinas , Quipazina/farmacologia , Ratos , Ratos Sprague-Dawley , Trazodona/farmacologia
2.
Res Commun Chem Pathol Pharmacol ; 77(1): 87-93, 1992 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-1359615

RESUMO

Olanzapine, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-B] [1,5]benzodiazepine (LY170053), antagonized the quipazine-induced elevation of serum corticosterone concentration in rats with an ED50 value of 0.57 mg/kg i.p. LY170053 was less potent in antagonizing the pergolide-induced elevation of serum corticosterone concentration in rats, and increases in corticosterone elicited by olanzapine alone at higher doses complicated the precise estimate of an ED50 value, which was approximately 3 mg/kg. These relative potencies in blocking quipazine and pergolide effects are taken as indices of antagonism of serotonin 5HT2 and of dopamine D2 receptors, respectively. Olanzapine is more potent than clozapine in blocking 5HT2 and D2 receptors, and its ability to block these receptors supports its possible usefulness as an antipsychotic drug.


Assuntos
Antagonistas de Dopamina , Pirenzepina/análogos & derivados , Antagonistas da Serotonina , Animais , Antipsicóticos/farmacologia , Benzodiazepinas , Clozapina/farmacologia , Corticosterona/sangue , Avaliação Pré-Clínica de Medicamentos , Masculino , Sistemas Neurossecretores/efeitos dos fármacos , Olanzapina , Pergolida/farmacologia , Pirenzepina/farmacologia , Quipazina/farmacologia , Ratos , Ratos Endogâmicos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA